Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 1,163 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 1,163 shares of KalVista Pharmaceuticals stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $15.00, for a total value of $17,445.00. Following the completion of the transaction, the insider owned 133,087 shares in the company, valued at $1,996,305. This trade represents a 0.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

KalVista Pharmaceuticals Stock Up 2.8%

Shares of KALV stock traded up $0.44 during mid-day trading on Thursday, hitting $15.89. 827,882 shares of the stock traded hands, compared to its average volume of 656,926. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.23 and a 52-week high of $19.00. The stock has a market cap of $803.24 million, a P/E ratio of -4.02 and a beta of -0.19. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The stock’s fifty day moving average is $15.52 and its two-hundred day moving average is $13.87.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently made changes to their positions in KALV. Invesco Ltd. raised its stake in KalVista Pharmaceuticals by 23.1% in the 4th quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock worth $1,258,000 after acquiring an additional 14,621 shares during the last quarter. XTX Topco Ltd purchased a new stake in KalVista Pharmaceuticals during the 4th quarter valued at about $428,000. Vestal Point Capital LP increased its holdings in shares of KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after purchasing an additional 1,140,000 shares during the period. Virtus Investment Advisers LLC raised its stake in shares of KalVista Pharmaceuticals by 364.9% in the fourth quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company’s stock worth $653,000 after purchasing an additional 31,721 shares during the last quarter. Finally, Squadron Capital Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the fourth quarter worth about $11,305,000.

Analysts Set New Price Targets

Several equities research analysts have weighed in on KALV shares. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Citizens Jmp decreased their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Tuesday, November 11th. Needham & Company LLC raised their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $29.40.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.